Physician profile
Maha Abboud
NPI 1346208956
$218,677.39
in general payments reported to CMS, 2019-2025
22 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $20K · 2021: $22K · 2022: $16K · 2023: $16K · 2024: $14K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $4,890 · Travel and Lodging: $3,178 · Food and Beverage: $2,640 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,007.50 |
| Consulting Fee | $4,890.00 |
| Travel and Lodging | $3,177.99 |
| Food and Beverage | $2,639.89 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88,380.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $54,071.44 | 2019-2020 | |
| Amgen INC. | $35,237.60 | 2019-2025 | Tepezza |
| Sanofi-Aventis U.S. LLC | $17,026.49 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $15,504.03 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $3,622.30 | 2019-2021 | |
| Abbott Laboratories | $2,555.52 | 2019-2024 | Freestyle Libre 3, Proclaim, Eterna |
| Dexcom, INC. | $499.12 | 2019-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $490.20 | 2022-2025 | |
| Insulet Corporation | $476.13 | 2019-2024 | Omnipod |
| Corcept Therapeutics | $326.61 | 2021-2025 | Korlym |
| Abbvie INC. | $104.98 | 2021-2023 | Synthroid |
| Xeris Pharmaceuticals, INC. | $62.85 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Sequel Med Tech, LLC | $61.18 | 2025 | Twiist |
| Lilly USA, LLC | $55.45 | 2022-2023 | Jardiance, Zepbound |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $50.49 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $45.10 | 2025 | Unithroid |
| Beta Bionics, INC. | $29.51 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Horizon Therapeutics Plc | $25.87 | 2023 | Tepezza |
| Allergan, INC. | $23.80 | 2022 | |
| Currax Pharmaceuticals LLC | $14.33 | 2023 | Nexletol, Contrave, Nexlizet |
| Phathom Pharmaceuticals, INC. | $14.26 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maha Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.